XML 42 R29.htm IDEA: XBRL DOCUMENT v3.21.1
The Company (Details)
3 Months Ended
Mar. 31, 2021
Segment
product
Oct. 31, 2020
USD ($)
Sep. 30, 2019
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Line Items]      
Number of operating segments | Segment 1    
Number of FDA approved products | product 2    
Collaborative Arrangement      
Organization, Consolidation and Presentation of Financial Statements [Line Items]      
Upfront payment receivable   $ 50,000,000.0  
Convertible notes      
Organization, Consolidation and Presentation of Financial Statements [Line Items]      
Principal amount     $ 316,250,000
Interest rate     1.50%